{"id":7368,"date":"2026-02-10T02:53:23","date_gmt":"2026-02-10T02:53:23","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/7368\/"},"modified":"2026-02-10T02:53:23","modified_gmt":"2026-02-10T02:53:23","slug":"complete-sham-novo-nordisk-sues-hims-hers","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/7368\/","title":{"rendered":"‘Complete Sham:’ Novo Nordisk Sues Hims & Hers"},"content":{"rendered":"


\n Novo Nordisk has taken its fight over weight-loss drugs to federal court, targeting telehealth company Hims & Hers over what it calls unauthorized copycats of Wegovy and Ozempic. In a lawsuit filed Monday, the Danish drugmaker asked a court to block Hims & Hers from selling compounded versions of its obesity and diabetes medications and to award damages, reports the Wall Street Journal<\/a>. Novo Nordisk argues that the products marketed by Hims & Hers bypass the FDA’s standard approval process and therefore have not undergone the agency’s full safety and efficacy review. The case reflects broader tensions over a booming market for weight-loss drugs and cheaper alternatives. \n <\/p>\n


\n “This is a complete sham, and it has been a sham since the shortage ended,” Novo attorney John Kuckelman tells CNBC. “The fact is that their medicines are untested, and they’re putting patients at risk.” Hims & Hers has defended compounded drugs, saying Novo Nordisk’s actions could harm patients who depend on those options. The telehealth firm had announced plans last week to sell a less expensive compounded version of Novo Nordisk’s new Wegovy pill before backing away from that rollout<\/a> over the weekend under regulatory and legal pressure. \n <\/p>\n


\n The company still offers compounded injectables, which do not contain Novo Nordisk’s FDA-approved semaglutide and are positioned as alternatives to Wegovy and Ozempic. The FDA commissioner has vowed to crack down on illegal copycats, and federal health officials have referred Hims & Hers to the Justice Department for a potential investigation under the Food, Drug, and Cosmetic Act. Compounding pharmacies are allowed to make versions of drugs when there are shortages or when a customized formulation is medically necessary. Novo Nordisk’s products were removed from the FDA’s shortage list early last year, but compounded versions have continued to be sold. \n <\/p>\n","protected":false},"excerpt":{"rendered":" Novo Nordisk has taken its fight over weight-loss drugs to federal court, targeting telehealth company Hims &…\n","protected":false},"author":2,"featured_media":7369,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[325,3846,272,3102,1910],"class_list":{"0":"post-7368","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-fda","9":"tag-lawsuit","10":"tag-novo-nordisk","11":"tag-ozempic","12":"tag-wegovy"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/7368","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=7368"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/7368\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/7369"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=7368"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=7368"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=7368"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}